arrow
F

Francisco Vega

The University of Texas MD Anderson Cancer Center
H指数:56
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

SMART START试验的长期临床结果:利妥昔单抗、来那度胺和伊布替尼在 newly diagnosed large B-cell lymphoma 患者中的应用

2026-07-020
OAAI
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses

IA期NLPHL患者的临床结局:全球NLPHL工作组(GLOW)回顾性分析

2026-04-160
OAAI
Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort Study

系统性外周T细胞淋巴瘤的治疗模式与临床结局:LEO-MER前瞻性队列研究

2026-02-200
OAAI
Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma

多模态空间表征肿瘤免疫微环境,识别弥漫性大B细胞淋巴瘤中可靶向的炎症微环境

2025-10-210
OAAI
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

作者更正: 同种异体NK细胞与双特异性先天细胞衔接器治疗难治性复发性淋巴瘤: 1期试验

2025-06-260
PRE
Large B cell lymphoma microenvironment archetype profiles

大B细胞淋巴瘤微环境原型图谱

2025-06-180
OA
Primary Cutaneous CD30-Positive Lymphoproliferative Disorders with IRF4/DUSP22Associated Chromosomal Alterations, including Rearrangements, Gains, and Deletions: A Clinicopathological, Immunohistochemical, and Molecular Analysis of 22 Patients
2025-03-010
PRE
Refining Diagnostic Subtypes of Peripheral T-Cell Lymphoma Using a Multiparameter Approach

使用多参数方法细化外周T细胞淋巴瘤的诊断亚型

2025-02-010
PRE
Vitamin D in patients with low tumor-burden indolent non- Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial
2024-12-011
OAAI
Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases

在Mycosis Fungoides和Sezary Syndrome中的大细胞转化:445例分析

BLOOD
IF23.1
2024-11-050
PRE
Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

基于Brentuximab Vedotin、Pembrolizumab、Doxorubicin和Dacarbazine的晚期经典霍奇金淋巴瘤PET适应性降级化疗方案:一项关于安全性与有效性的II期研究

BLOOD
IF23.1
2024-11-050
PRE
Venetoclax As a Combination Partner with NAMPT Inhibitor Rpt-1G for T-ALL

维奈克拉司(Venetoclax)作为NAMPT抑制剂Rpt-1G的联合治疗伙伴用于T-ALL

BLOOD
IF23.1
2024-11-050
PRE